Brief: Y-Mabs' Danyelza For Treatment Of High-Risk Neuroblastoma Approved In China

Y-mAbs Therapeutics

08/12/2022 17:18

Dec 8 (Reuters) - Y-mAbs Therapeutics Inc  YMAB.O :
    * Y-MABS’ DANYELZA® (NAXITAMAB-GQGK) FOR THE TREATMENT OF
HIGH-RISK NEUROBLASTOMA APPROVED IN CHINA
    * Y-MABS THERAPEUTICS INC - DANYELZA WILL BE MARKETED IN
CHINA BY
Y-MABS' PARTNER SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED

Source text for Eikon:  ID:nGNX6sTZq0 
Further company coverage:  YMAB.O 
 ((Reuters.Briefs@thomsonreuters.com;))